[{"address1": "7750 El Camino Real", "address2": "Suite 2A", "city": "Carlsbad", "state": "CA", "zip": "92009", "country": "United States", "phone": "858 704 4900", "website": "https://www.palisadebio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. J. D. Finley", "age": 65, "title": "CEO, CFO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 791333, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mitchell Lawrence Jones M.D., Ph.D.", "age": 45, "title": "COO & Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 635002, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joerg  Heyer Ph.D.", "title": "Head of Translational Science & Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryker  Willie", "title": "Senior VP of Finance & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.99, "open": 3.9094, "dayLow": 3.9094, "dayHigh": 4.0899, "regularMarketPreviousClose": 3.99, "regularMarketOpen": 3.9094, "regularMarketDayLow": 3.9094, "regularMarketDayHigh": 4.0899, "beta": 1.301, "forwardPE": -0.44717103, "volume": 9292, "regularMarketVolume": 9292, "averageVolume": 65169, "averageVolume10days": 22830, "averageDailyVolume10Day": 22830, "bid": 2.88, "ask": 5.18, "bidSize": 200, "askSize": 200, "marketCap": 4830587, "fiftyTwoWeekLow": 3.3, "fiftyTwoWeekHigh": 22.35, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 3.8528, "twoHundredDayAverage": 5.90255, "currency": "USD", "enterpriseValue": -6192966, "floatShares": 1162989, "sharesOutstanding": 1184490, "sharesShort": 49486, "sharesShortPriorMonth": 111888, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0418, "heldPercentInsiders": 0.022869999, "heldPercentInstitutions": 0.028859999, "shortRatio": 2.24, "shortPercentOfFloat": 0.0421, "bookValue": 10.293, "priceToBook": 0.396211, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -14190000, "trailingEps": -18.57, "forwardEps": -9.12, "lastSplitFactor": "1:6", "lastSplitDate": 1619568000, "enterpriseToEbitda": 0.425, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PALI", "underlyingSymbol": "PALI", "shortName": "Palisade Bio, Inc.", "longName": "Palisade Bio, Inc.", "firstTradeDateEpochUtc": 1175261400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "48a6a4f2-9a74-360b-918d-da0f22330672", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.0782, "targetHighPrice": 45.0, "targetLowPrice": 22.5, "targetMeanPrice": 33.75, "targetMedianPrice": 33.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 11353000, "totalCashPerShare": 9.585, "ebitda": -14588000, "totalDebt": 503000, "quickRatio": 4.048, "currentRatio": 4.341, "debtToEquity": 5.056, "returnOnAssets": -0.58531, "returnOnEquity": -1.10094, "freeCashflow": -7663750, "operatingCashflow": -12087000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-17"}]